...
首页> 外文期刊>Tumour biology : >Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population
【24h】

Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population

机译:表皮生长因子受体2过表达对浸润性小叶乳腺癌患者预后的强烈不良影响:中国人群浸润性导管癌的比较研究

获取原文
获取原文并翻译 | 示例
           

摘要

The data on the outcome of breast invasive lobular carcinoma (ILC) are conflicting. In addition, the prognostic effect of molecular subtypes on ILC remains unclear. In this study, the clinicopathological and prognostic data between 269 ILC and 816 invasive ductal carcinoma (IDC) cases in a Chinese population were extensively compared, with a median follow-up time of 7.8 years. Compared with the IDC group, ILC tumors had more lymph node invasion, hormonal receptor positivity, and human epidermal growth factor receptor 2 (HER2) negativity. ILC patients showed overall survival (OS) and recurrence/metastasis-free survival (RFS) rates similar to those of IDC patients but exhibited worse disease-free survival (DFS) rate because of the higher rate of contralateral breast cancer (BC). Further analysis showed that OS, RFS, and DFS were similar between ILC and IDC patients in the subgroups of luminal A and triple-negative BC with HER2 negativity but were worse in ILC patients than those in IDC patients in the subgroups of luminal B and HER2 overexpression with positive HER2 expression. Multivariate analysis indicated HER2 positivity as an independent risk factor for OS, RFS, and DFS of ILC patients, which increased the risk in the ILC group than that in IDC group. The interaction of HER2 and ILC was also defined as an independent risk factor for OS, RFS, and DFS of the entire population. In conclusion, overexpression of HER2 exhibited stronger negative effect on the prognosis of ILC patients than that in IDC patients, suggesting that treatment targeting HER2 is crucial for this BC subgroup.
机译:关于乳腺浸润性小叶癌(ILC)结局的数据相互矛盾。此外,分子亚型对ILC的预后影响尚不清楚。在这项研究中,对中国人群中269例ILC和816例浸润性导管癌(IDC)病例之间的临床病理和预后数据进行了广泛比较,中位随访时间为7.8年。与IDC组相比,ILC肿瘤具有更多的淋巴结浸润,激素受体阳性和人表皮生长因子受体2(HER2)阴性。 ILC患者的总体生存率(OS)和无复发/无转移生存率(RFS)与IDC患者相似,但由于对侧乳腺癌(BC)的患病率较高,因此无病生存率(DFS)较差。进一步的分析表明,管腔A和三阴性BC亚组的HER2阴性的ILC和IDC患者的OS,RFS和DFS相似,但管腔B和HER2亚组的ILC患者的ID,OSC,RFS和DFS较IDC患者差HER2阳性表达的过表达。多因素分析表明,HER2阳性是ILC患者OS,RFS和DFS的独立危险因素,与IDC组相比,ILC组患病风险增加。 HER2和ILC的相互作用也被定义为整个人群OS,RFS和DFS的独立危险因素。总之,与IDC患者相比,HER2过表达对ILC患者的预后表现出更强的负面影响,这表明靶向HER2的治疗对该BC亚组至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号